GRANULES · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 43/100 — Quality 62 · Valuation 2 · Growth 24 · Momentum 100
| Share price | ₹876.10 |
| Market cap | ₹14,131 Cr |
| P/E ratio | 25.9 |
| P/B ratio | 3.5 |
| ROCE | 16.0% |
| Dividend yield | 0.26% |
| Book value | ₹164.06 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹5,366 Cr | ₹595 Cr | 22.0% |
| 2025 | ₹4,482 Cr | ₹502 Cr | 21.0% |
| 2024 | ₹4,506 Cr | ₹405 Cr | 19.0% |
| 2023 | ₹4,512 Cr | ₹517 Cr | 20.0% |
| 2022 | ₹3,765 Cr | ₹413 Cr | 19.0% |
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. It offers paracetamol, metformin, guaifenesin, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. The company offers its products